Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of IBP-9414 in Preterm Infants
NCT02472769Phase 2Completed
- Sponsor
- Infant Bacterial Therapeutics
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of IBP-9414 in necrotizing enterocolitis (NEC), sponsored by Infant Bacterial Therapeutics. Started May 2016; status: completed.
02
Drugs
IBP-9414
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT02472769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472769.